BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 22500026)

  • 1. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
    Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
    J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
    Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
    J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
    Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
    Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
    Nishioku T; Kubo T; Kamada T; Okamoto K; Tsukuba T; Uto T; Shoyama Y
    Biomed Res; 2020; 41(6):269-277. PubMed ID: 33268671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
    Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
    J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating calcium-mediated NFATc1 and mitogen-activated protein kinase deactivation underlies the inhibitory effects of kavain on osteoclastogenesis and bone resorption.
    Guo Q; Cao Z; Wu B; Chen F; Tickner J; Wang Z; Qiu H; Wang C; Chen K; Tan R; Gao Q; Xu J
    J Cell Physiol; 2018 Jan; 234(1):789-801. PubMed ID: 30078210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein receptor deficiency reduced bone mass in mice via the c-fos/NFATc1 pathway.
    Qi Q; Chen L; Sun H; Zhang N; Zhou J; Zhang Y; Zhang X; Li L; Li D; Wang L
    Life Sci; 2022 Dec; 310():121073. PubMed ID: 36244411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RARγ is a negative regulator of osteoclastogenesis.
    Green AC; Poulton IJ; Vrahnas C; Häusler KD; Walkley CR; Wu JY; Martin TJ; Gillespie MT; Chandraratna RA; Quinn JM; Sims NA; Purton LE
    J Steroid Biochem Mol Biol; 2015 Jun; 150():46-53. PubMed ID: 25800721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
    Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
    J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.
    Deepak V; Kruger MC; Joubert A; Coetzee M
    Biofactors; 2015; 41(6):403-13. PubMed ID: 26627060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.
    Liou SF; Hsu JH; Lin IL; Ho ML; Hsu PC; Chen LW; Chen IJ; Yeh JL
    PLoS One; 2013; 8(7):e69468. PubMed ID: 23936022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid zinc finger 1 knockdown promotes osteoclastogenesis and bone loss in part by regulating RANKL-induced ferroptosis of osteoclasts through Nrf2/GPX4 signaling pathway.
    Qu Z; Zhang B; Kong L; Zhang Y; Zhao Y; Gong Y; Gao X; Feng M; Zhang J; Yan L
    J Leukoc Biol; 2024 Apr; 115(5):946-957. PubMed ID: 38266238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor activator of NF-κB ligand-dependent expression of caveolin-1 in osteoclast precursors, and high dependency of osteoclastogenesis on exogenous lipoprotein.
    Hada N; Okayasu M; Ito J; Nakayachi M; Hayashida C; Kaneda T; Uchida N; Muramatsu T; Koike C; Masuhara M; Sato T; Hakeda Y
    Bone; 2012 Jan; 50(1):226-36. PubMed ID: 22075210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
    Kim EC; Park J; Noh G; Park SJ; Noh K; Kwon IK; Ahn SJ
    Bioelectromagnetics; 2018 Jul; 39(5):394-404. PubMed ID: 29709064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis.
    Miyauchi Y; Ninomiya K; Miyamoto H; Sakamoto A; Iwasaki R; Hoshi H; Miyamoto K; Hao W; Yoshida S; Morioka H; Chiba K; Kato S; Tokuhisa T; Saitou M; Toyama Y; Suda T; Miyamoto T
    J Exp Med; 2010 Apr; 207(4):751-62. PubMed ID: 20368579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.